Advanced Testing in Charleston and Mt. Pleasant, SC

Reviewed by Ashley Harwyn, PA-C  |  A4M Board Certified  |  Updated September 4, 2026

Most pages about advanced testing are a menu. This one is about how to decide what belongs on yours, including the parts of our own menu where the evidence is thinner than the marketing usually admits.

What makes a test worth running?

Two questions, asked before the draw rather than after it. What would a positive result change, and what would a negative one rule out? If neither answer is concrete, the test is producing information rather than answering a question, and information you cannot act on has a cost without a benefit.

The second filter is public. The US Preventive Services Task Force grades screening tests for adults without symptoms, and those grades are the closest thing this field has to a scorecard. They are worth knowing because almost nobody selling a panel volunteers them.

Which tests here carry a recommendation?

Screening for prediabetes and type 2 diabetes is a grade B for adults aged 35 to 70 who have overweight or obesity, and the Task Force lowered that starting age from 40 to 35 in 2021[3]. A grade B means moderate net benefit. It is cheap, it is quick, and a positive result changes the plan immediately.

Lipids sit inside a decision rather than standing alone. The Task Force recommends a statin for primary prevention in adults aged 40 to 75 who have at least one cardiovascular risk factor and an estimated ten-year risk of 10 percent or greater, a grade B[2]. Between 7.5 and under 10 percent it recommends offering one selectively, a grade C. For adults 76 and older the evidence is insufficient to say[2]. That is why a lipid panel is read alongside your age, blood pressure and history rather than against a reference range in isolation. See advanced lipid testing.

The most common test with the least agreement

Vitamin D is the clearest example of a popular test with no formal backing for routine use. For asymptomatic, community-dwelling, nonpregnant adults, the Task Force concludes the evidence is insufficient to assess the balance of benefits and harms of screening for vitamin D deficiency, a grade I[1].

The reason it gives is more useful than the grade. Vitamin D requirements vary between individuals, no single serum level defines deficiency, and no consensus exists on the levels that represent sufficiency[1]. So two labs can flag the same number differently, and a result that looks low is not automatically a condition.

Why running everything is not the safe option

It feels thorough, which is why it sells. The problem is arithmetic. Every test has a false positive rate, and the more tests you run at once, the higher the chance that at least one comes back abnormal in a completely healthy person.

An abnormal result nobody expected does not stay on the page. It generates a repeat test, sometimes imaging, sometimes a referral, always cost, and reliably some worry, for something that in many cases was never going to affect you. That is the harm side of the balance the Task Force keeps referring to, and it is real even though it never appears on a menu.

What a reference range is, and what it is not

A reference range is not a target. For most analytes it is the middle 95 percent of results from a reference population, which means one in twenty healthy people falls outside it by definition. Being slightly out of range is common, expected, and frequently meaningless.

A decision threshold is a different animal. It is a number chosen because crossing it changes what should happen, and it comes from outcome data rather than from a population spread. A total testosterone of 300 ng/dL and a ten-year cardiovascular risk of 10 percent are decision thresholds[2]. A vitamin D level is not one, because no consensus exists on what the number should be[1].

This distinction is where most of the confusion in wellness testing lives. A panel printed with red flags against every out-of-range value looks alarming and is usually describing normal biological variation. The useful question is never whether a value sits inside a band. It is whether the value crosses a threshold that changes a decision.

Testing that is worth repeating

Some measurements are far more useful as a trend than as a snapshot, and that changes how they should be ordered. A single body composition reading tells you where you are; the same measurement three months later tells you whether a plan is working, which is the part that actually informs anything. A scale cannot do that, because it cannot separate muscle from fat or from water. See body composition analysis.

The same logic applies to blood sugar, lipids and thyroid function once a treatment has started. Repeating a short, targeted panel on a schedule is usually cheaper than one broad panel and considerably more informative, because you are measuring a direction rather than a point. It also has a natural stopping rule: when the number stops moving and the symptoms have settled, the testing can stop too.

What a grade does and does not mean

The distinction that gets lost most often is between screening and investigating. The Task Force grades screening: testing people who have no symptoms. A test ordered because of a specific symptom, a family history or an abnormal earlier result is a different activity, and it is judged on whether it changes what happens next. Plenty of valuable testing has no grade simply because it was never a screening question.

How a panel gets chosen in Mount Pleasant and Charleston

History first, and it takes as long as it takes, because the history is what narrows the list. Then a panel built from that, which for most people is shorter than they expected and more specific. Then a conversation about the results that says what each one means, what it does not mean, and what changes because of it.

Testing visits can be scheduled at either of our two offices. If you have had testing elsewhere, bring it, including the times of day the samples were drawn, because several analytes move through the day and a result read without that context can be misleading.

Tests we will not sell you

We will not sell a fixed panel that includes tests answering no question you have, and we will not present a grade I test as though it were settled science[1]. If a result cannot be acted on, it was not worth the draw, and saying so before the order is placed is the whole point of this page.

Questions people actually ask

Ashley Harwyn, PA-C A4M Board Certified · Founder, Solcara Health Online

Tap a question to ask

About the author

Ashley Harwyn, PA-C

Founder, Solcara Health · Board Certified in Anti-Aging and Functional Medicine (A4M)

Ashley has practiced medicine for more than fifteen years. Her path into it began at home, with a family member born with a congenital heart defect and a childhood spent watching how much the quality of a clinician's attention could change the shape of a life. She has since practiced across a range of settings, including medical mission work in Uganda, before founding Solcara to build the kind of practice she kept wishing existed, one that treats women as whole people and tells them the truth about what the evidence does and does not support.

Full bio →